triazolam has been researched along with Lung Diseases, Obstructive in 5 studies
Triazolam: A short-acting benzodiazepine used in the treatment of insomnia. Some countries temporarily withdrew triazolam from the market because of concerns about adverse reactions, mostly psychological, associated with higher dose ranges. Its use at lower doses with appropriate care and labeling has been reaffirmed by the FDA and most other countries.
Lung Diseases, Obstructive: Any disorder marked by obstruction of conducting airways of the lung. AIRWAY OBSTRUCTION may be acute, chronic, intermittent, or persistent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Triazolam was more effective than zolpidem 5 mg but not zolpidem 10 mg, and there was no significant difference between zolpidem 5 mg and zolpidem 10 mg." | 2.67 | Effects of zolpidem and triazolam on sleep and respiration in mild to moderate chronic obstructive pulmonary disease. ( George, CF; Kryger, MH; Millar, TW; Pouliot, Z; Steens, RD, 1993) |
| "In patients without severe waking hypoxemia and without carbon dioxide retention, triazolam did not increase either nocturnal hypoxemia or respiratory events during sleep." | 2.66 | Effect of triazolam on sleep and arterial oxygen saturation in patients with chronic obstructive pulmonary disease. ( Dawson, A; Hajdukovic, RM; Mitler, MM; Timms, RM, 1988) |
| "The long-term use of benzodiazepine hypnotics by the elderly is associated with serious side effects, and prescriptions of large quantities of these agents allow such use." | 1.28 | Failure to limit quantities of benzodiazepine hypnotic drugs for outpatients: placing the elderly at risk. ( Bauwens, SF; Landefeld, CS; Shorr, RI, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 4 (80.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Steens, RD | 1 |
| Pouliot, Z | 1 |
| Millar, TW | 1 |
| Kryger, MH | 1 |
| George, CF | 1 |
| Murciano, D | 2 |
| Armengaud, MH | 1 |
| Cramer, PH | 1 |
| Neveux, E | 1 |
| L'Héritier, C | 1 |
| Pariente, R | 2 |
| Aubier, M | 2 |
| Shorr, RI | 1 |
| Bauwens, SF | 1 |
| Landefeld, CS | 1 |
| Palacios, S | 1 |
| Timms, RM | 1 |
| Dawson, A | 1 |
| Hajdukovic, RM | 1 |
| Mitler, MM | 1 |
3 trials available for triazolam and Lung Diseases, Obstructive
| Article | Year |
|---|---|
Effects of zolpidem and triazolam on sleep and respiration in mild to moderate chronic obstructive pulmonary disease.
Topics: Adult; Aged; Chronic Disease; Double-Blind Method; Female; Humans; Hypnotics and Sedatives; Lung Dis | 1993 |
Acute effects of zolpidem, triazolam and flunitrazepam on arterial blood gases and control of breathing in severe COPD.
Topics: Blood Gas Analysis; Carbon Dioxide; Flunitrazepam; Humans; Hypnotics and Sedatives; Lung Diseases, O | 1993 |
Effect of triazolam on sleep and arterial oxygen saturation in patients with chronic obstructive pulmonary disease.
Topics: Aged; Double-Blind Method; Female; Humans; Hypercapnia; Hypoxia; Lung Diseases, Obstructive; Male; M | 1988 |
2 other studies available for triazolam and Lung Diseases, Obstructive
| Article | Year |
|---|---|
Failure to limit quantities of benzodiazepine hypnotic drugs for outpatients: placing the elderly at risk.
Topics: Age Factors; Aged; Attitude of Health Personnel; Cross-Sectional Studies; Drug Prescriptions; Drug U | 1990 |
Comparison of zolpidem (Z), triazolam (T), and flunitrazepam (F) effects on arterial blood gases and control of breathing in patients with severe chronic obstructive pulmonary disease (COPD).
Topics: Flunitrazepam; Humans; Hypnotics and Sedatives; Lung Diseases, Obstructive; Pyridines; Respiratory C | 1990 |